Clinical Research Directory
Browse clinical research sites, groups, and studies.
Leveraging Pharmacogenomics in Asthma for Predication, Mechanism and Endotyping
Sponsor: University of California, San Diego
Summary
In this study, a new method will be used to evaluate response to 2 approved biologic therapies, and assess how well each patient responds to each asthma treatment. This study will measure the response to these treatments using genomic and biologic measurements obtained from participants biosamples. By evaluating response to 2 different biologic therapies, this study has the potential to provide an in-depth understanding of the mechanisms underlying severe asthma that will inform and change treatment decisions, and may ultimately lead to a change in the way that asthma patients are evaluated for potential personalized therapies and maximize the probability that the subject will respond to treatment.
Key Details
Gender
All
Age Range
18 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
120
Start Date
2024-02-19
Completion Date
2028-01-31
Last Updated
2024-08-19
Healthy Volunteers
No
Conditions
Interventions
Dupilumab
Dupilumab, an interleukin-4 receptor treatment, will be administered through a subcutaneous injection, the initial dose of 600 mg will be administered at two different injection sites (300 mg per injection), followed by a single dose of 300 mg administered every other week (Q2W). Participants may self-administer injection after proper training.
Benralizumab
Benralizumab, an interleukin-5 receptor treatment, will be administered through a subcutaneous injection every 4 weeks (Q4W). Participants may self-administer injection after proper training.
Locations (3)
Mayo Clinic
Scottsdale, Arizona, United States
University of California, San Diego
La Jolla, California, United States
Yale University
New Haven, Connecticut, United States